Physician profile
Daniel Gordon
NPI 1467862813
$962.08
in general payments reported to CMS, 2019-2025
18 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.90 · 2021: $69.28 · 2022: $162 · 2023: $117 · 2024: $154 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264.94 | 2022-2025 | |
| Lilly USA, LLC | $120.06 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $71.95 | 2022-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $57.36 | 2023-2025 | |
| Alkermes, INC. | $57.08 | 2023 | Vivitrol |
| Stryker Corporation | $54.26 | 2025 | Clottriever Bold Catheter |
| Amgen INC. | $50.61 | 2022-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $49.15 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi Pasteur INC. | $41.23 | 2019-2021 | |
| Glaxosmithkline, LLC. | $38.41 | 2022-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $30.12 | 2019-2024 | Rybelsus, Ozempic |
| Medtronic, INC. | $28.23 | 2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $19.36 | 2025 | Keveyis |
| Dexcom, INC. | $18.75 | 2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $17.72 | 2025 | Qelbree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.